Mediterr J Rheumatol 2018;29(2):80-5
Association of Monoclonal Gammopathy of Undetermined Significance with Behcet’s Disease: A Review of Shared Common Disease Pathogenetic Mechanisms
Authors Information
Department of Rheumatology, St Barts & The Royal London Hospital, London, United Kingdom
  1. Zingone A, Kuehl W M. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2001;48:4-12.
  2. McShane C M, Murray L, Landgren O, O’Rorke M A, Korde N, Kunzmann A T, et al. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomarkers Prev 2014;23:332-42.
  3. Brown L M, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008;111:3388-94.
  4. Raposo A, Peixoto D, Bogas M. Monoclonal gammopathy and rheumatic diseases. Acta Reumatol Port 2014;39:12-8.
  5. Bida J P, Kyle R A, Therneau T M, Melton J L, Plevak M F, Larson D R, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009;84:685-93.
  6. Lindqvist E K, Goldin L R, Landgren O, Blimark C, Mellqvist U H, Turesson I, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 2011;118:6284-91.
  7. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003;82:60-76.
  8. Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology 2006;45:1461-5.
  9. Vaiopoulos G, Terpos E, Viniou N, Nodaros K, Rombos J, Loukopoulos D. Behcet’s disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: A case report and review of the literature. Am J Hematol 2001;661:57-8.
  10. Goodnow C C. Multistep pathogenesis of autoimmune disease. Cell 2007;130:25-35.
  11. Zeidan M J, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: a contemporary review. Auto Immun 2016;7:4.
  12. Takeuchi M, Kastner DL, Remmers E F. The immunogenetics of Behçet’s disease: A comprehensive review. J Autoimmun 2015;4:137-48.
  13. Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet’s disease. Arthritis Rheum 1999;42:1961-6.
  14. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nature Genet 2010;42:703-6.
  15. Ghoreschi K, Laurence A, Yang X, Hirahara K, O’Shea J J. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011;32:395-401.
  16. Zheng C, Huang D, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M, et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000;109:39-45.
  17. Kyle R A. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997;11:71-87.
  18. Bladé J, Filella X, Montoto S, Bosch F, Rosiñol L, Coca F, et al. Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol 2002;117:387-9.
  19. Gadó K, Domján G, Hegyesi H, Falus A. Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 2000;24:195-209.
  20. Nguyen H N, Noss E H, Mizoguchi F, Huppertz C, Wei K S, Watts G F M, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity 2017;46:220-32.
  21. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behçet’s disease in Han Chinese in a genome-wide association study. Arthritis Rheum 2012;64:4104-13.
  22. Kirino Y, Remmers E F. Genetic architectures of seropositive and seronegative rheumatic diseases. Nat Rev Rheumatol 2015;11:401-14.
  23. Yu H, Lee D, Seo J M, Ahn J K, Yu Y S, Lee W S, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet’s uveitis. J Clin Exp Immunol 2004;137:437-43.
  24. Gon H, Jae Y, Ahn K, Chung H, Lee D, Yu Y S, et al. Uveitis Effectors in Patients with Active Behçet’s T Cells Are Cytotoxic + CD56 bright CD8 CD8 bright CD56 ؉ T Cells Are Cytotoxic Effectors in Patients with Active Behçet’s Uveitis. J Immunol 2005; 175:6133-42.
  25. Pittet M J, Speiser D E, Valmori D, Cerottini J C, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000;164:1148-52.
  26. Halapi E, Werner A, Wahlström J, Österborg A, Jeddi-Tehrani M, Yi Q, et al. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. Eur J Immunol 1997;27:2245-52.
  27. Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011;128:655-64.
  28. Hamzaoui K. Th17 cells in Behçet’s disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011;29:S71-6.
  29. Pekiner F N, Aytugar E, Demirel G Y, Borahan M O. Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet’s disease and recurrent aphthous ulcerations. J Oral Pathol Med 2012;41:73-9.
  30. Braga W M, Atanackovic D, Colleoni GWB (2012). The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Clin Dev Immunol 2012;1-4.
  31. Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008;93:423-30.
  32. Dhodapkar K M, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008;112:2878-85.
  33. Ogawara H, Handa H, Yamazaki T, Toda T, Yoshida K, Nishimoto N, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res 2005;29:135-40.
  34. Chambrun P, Wechsler M B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012;11:687-98.
  35. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006;20:1130-7.
  36. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet’s disease. Clin Exp Rheumatol 2003;21:S44-8.
  37. Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19:S6-12.
  38. Morton L T, Situnayake D, Wallace G R. Genetics of Behçetʼs disease. Curr Opin Rheumatol 2016;28:39-44.
  39. Zhou Q, Xiao X, Wang C, Zhang X, Li F, Zhou Y, et al. Decreased microRNA-155 Expression in ocular Behcet’s disease but not in Vogt Koyanagi Harada syndrome. Invest Ophthalmol Vis Sci 2012;53:5665-74.
  40. Hughes T, Ture-Ozdemir F, Alibaz-Oner F, Coit P, Direskeneli H, Sawalha A H. Epigenome-wide scan identifies a treatment-responsive pattern of altered dna methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behçet’s disease. Arthritis Rheum 2014;66:1648-58.
  41. Heuck C J, Mehta J, Bhagat J, Gundabolu K, Yu Y, Khan S, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol 2013;190:2966-75.
  42. Pichiorri F, Suh S, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885-90.